A phase II trial of micafungin and fluconazole against invasive fungal infections in hematopoietic stem cell transplant recipients

Trial Profile

A phase II trial of micafungin and fluconazole against invasive fungal infections in hematopoietic stem cell transplant recipients

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2016

At a glance

  • Drugs Fluconazole (Primary) ; Micafungin (Primary)
  • Indications Aspergillosis; Candidiasis; Mycoses
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jul 2016 Results published in the Journal of Infection
    • 19 Jan 2016 New trial record
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top